Search

Displaying results 231 - 240 of 4188 in total
  1. Drug

    Azilsartan medoxomil

    go.drugbank.com/drugs/DB08822
    ApprovedInvestigational

    [A7354] Many guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting

    Categories: Angiotensin II receptor blockers (ARBs), plain, Angiotensin II receptor blockers (ARBs) and diuretics
  2. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    [A187361] Elexacaftor, along with [VX-659], was designed to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and a gene that does not produce protein or … corrector/potentiator combination therapy has proven useful in the treatment of a subset of CF patients,[A187358] their use is typically limited to patients who are homozygous for the _F508del-CFTR_ gene

  3. Drug

    Talc

    go.drugbank.com/drugs/DB09511
    ApprovedInvestigational

    Although talc has been widely used for decades, lawsuits that have come to the surface claim serious health complications linked to its use.

  4. Drug

    Disulfiram

    go.drugbank.com/drugs/DB00822
    ApprovedInvestigational

    It acts by inhibiting aldehyde dehydrogenase.

  5. Drug

    Nonivamide

    go.drugbank.com/drugs/DB11324
    Approved

    This drug has been studied in combination with Nicarboxil in the treatment of lower back pain [L2642]. … Nonivamide has also been studied for its anti-inflammatory properties, as well as in fat loss therapies and has demonstrated promising results [L2643], [A32888], [A32886], [A32884].

  6. Drug

    Thiopental

    go.drugbank.com/drugs/DB00599
    ApprovedInvestigationalVet approvedWithdrawn

    Small doses have been shown to be anti-analgesic and lower the pain threshold. (From Martindale, The Extra Pharmacopoeia, 30th ed, p920) … It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties.

  7. Drug

    Memantine

    go.drugbank.com/drugs/DB01043
    ApprovedInvestigational

    Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a ...

  8. Drug

    Brimonidine

    go.drugbank.com/drugs/DB00484
    ApprovedInvestigational

    Brimonidine is an alpha-adrenergic agonist and 2-imidazoline derivative that was first introduced in 1996. It is considered to be a third generation alpha-2 aadrenergic receptor agonist, since it displays preferential binding at alpha-2 ...

  9. Drug

    Fomivirsen

    go.drugbank.com/drugs/DB06759
    ApprovedWithdrawn

    Fomivirsen is a antisense 21 mer phosphorothioate oligonucleotide. It is an antiviral agent that was used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS. As a complementary nu...

  10. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. … [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022.

    Categories: Calcitonin Gene-Related Peptide (CGRP) Antagonists, Calcitonin Gene-Related Peptide Receptor Antagonists